Ophthalmology has a peculiar prior-authorization problem: the payers almost always say yes. The friction isn’t the denial — it’s everything that happens before the inevitable approval, repeated on a schedule, for a therapy where waiting can cost a patient their sight.
The drug class at the center of it is anti-VEGF — the injections that hold back wet age-related macular degeneration and diabetic macular edema.
The numbers in retina care
A 2024 study in JAMA Ophthalmology examined prior authorization for anti-VEGF therapy in retina practices and found a pattern that should not survive contact with common sense:
- ~96% of anti-VEGF authorizations were ultimately approved.
- 60% were delayed by at least 24 hours.
- 64% were re-authorizations — the same drug, the same patient, re-justified.
- 12% of delayed authorizations took 31 days or more.
Layer on the general burden every physician carries — 39 authorizations a week, roughly 13 hours lost to them, 93% reporting that PA delays care (AMA 2024) — and you have a specialty spending enormous effort to obtain approvals the payer was always going to grant.
Why ophthalmology is different
- Time-sensitive anatomy. In wet AMD and DME, delayed treatment risks permanent vision loss. A 31-day wait isn’t an administrative footnote; it’s a window in which the retina changes.
- Recurring injections. Anti-VEGF is given in a maintenance series. Each payer’s re-authorization requirement turns ongoing care into a recurring paperwork cycle, and a lapsed re-auth interrupts the schedule.
- Buy-and-bill. Many of these drugs are administered and billed in-office, so an authorization delay stalls the injection visit itself.
What it costs
The clearest cost is clinical: vision that doesn’t come back. The operational cost is the staff time spent assembling and re-assembling near-identical justifications, multiplied across a high-volume injection practice — at roughly $10.81 per manually processed authorization (CAQH 2023), the re-authorization churn alone is a standing expense. And there’s the absurdity tax: a 96% approval rate means almost all of that effort produces an outcome that was never in doubt.
How to cut the wait
When the justification is consistent and the payer criteria are knowable, the authorization is software’s job, not a technician’s. Artificer Health:
- Assembles the clinical packet — diagnosis, imaging, prior injections, and the documentation each payer’s anti-VEGF policy requires.
- Matches it to the payer so the first submission meets that payer’s criteria.
- Tracks the recurring series, surfacing re-authorization deadlines before they lapse so the injection schedule never breaks for a paperwork reason.
The result: approvals in minutes instead of days, maintenance injections that stay on schedule, and a retina practice that spends its time on the macula instead of the fax machine.
Sources: Dang S et al., “Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices,” JAMA Ophthalmol 2024;142(8):716–721 (PMID 38935350); AMA 2024 Prior Authorization Physician Survey; CAQH 2023 Index.